Here's the latest variant picture with a global scope, to early November.
BA.3.* (mostly BA.3.2.2) has started showing significant signs of growth. Recent samples have mostly been reported from Germany and Australia.
Note I have rolled my reporting window forward an extra week, to capture this development. So recent samples are even thinner than usual.
Here's the latest variant picture for New Zealand, to late October.
In a chaotic scene, NB.1.8.1 "Nimbus" is being challenged by JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus". This scenario raises the risk of rapid reinfections, for those relying on immunity from a recent infection.
#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #XFG #Stratus
馃У
Here's the latest variant picture for New Zealand, to late October.
In a chaotic scene, NB.1.8.1 "Nimbus" is being challenged by JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus". This scenario raises the risk of rapid reinfections, for those relying on immunity from a recent infection.
#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #XFG #Stratus
馃У
Here's the latest variant picture with a global scope, to early November.
BA.3.* (mostly BA.3.2.2) has started showing significant signs of growth. Recent samples have mostly been reported from Germany and Australia.
Note I have rolled my reporting window forward an extra week, to capture this development. So recent samples are even thinner than usual.
Here's the latest variant picture with a global scope, to early June.
The LP.8.1., NB.1.8.1 "Nimbus" and XFG. "Stratus" variants are battling for dominance in an unclear picture.
XFG.* "Stratus" seemed to have the best underlying momentum, until recently when samples from the US became less dominant.
Here's the latest variant picture with a global scope, to early June.
The LP.8.1., NB.1.8.1 "Nimbus" and XFG. "Stratus" variants are battling for dominance in an unclear picture.
XFG.* "Stratus" seemed to have the best underlying momentum, until recently when samples from the US became less dominant.